| Date | Title | Description |
| 26.10.2023 | - | 3B FUTURE HEALTH GP S.a.r.l. is delighted to announce that 3B Future Health Fund II hosted its first investors’ meeting on October 4th, 2023 in Milan, Italy. |
| 18.04.2023 | - | London, UK, 18 April 2023, -NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that it has signed a strategic collaboration agreement with Professor Chris
Lord’s lab at The Institute of Cancer Research, L... |
| 14.04.2023 | - | NEWS PROVIDED BY |
| 19.01.2023 | - | Cambridge, UK, 19 January 2023 – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces the completion of its £21.5m (US $28.5m) Series B financing, with a £6m (US $7.5m) financing extension. The syndicate co... |
| 20.12.2022 | - | Funding will support iOnctura’s clinical program for IOA-289, a first-in-class autotaxin inhibitor for the treatment of cancer. |
| 17.11.2022 | - | PRESS RELEASE
Stockholm, Sweden, November 17, 2022
AnaCardio Receives Regulatory Approval to Start a Phase 1b/2a Clinical Study in Heart Failure with AC01 in the EU and UK
AnaCardio today announces approval for the GOAL-HF1 Phase 1b/2a stud... |
| 19.10.2022 | - | – Clinical trial applications accepted in France and Belgium for initiation of Phase I clinical trial
of DT-9081
– Domain’s first fully owned immuno-oncology program to enter the clinic by end of 2022
– Extensive biomarker strategy develope... |
| 11.10.2022 | - | October 04, 2022 05:00 AM Eastern Daylight Time |
| 22.09.2022 | - | Series A funding round initiated to further fund the clinical development of its “First In Class” small molecules against Uveal Melanoma and other indications fueled by hypervascularization and immunosuppressive inflammation. |
| 08.09.2022 | - | AnaCardio raises SEK 150 million to advance drug candidate AC01 in heart failure |
| 28.06.2022 | - | Strasbourg, France – Montreal, Canada, June 28, 2022 – Domain Therapeutics, a biopharmaceutical company focusing on the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), toda... |
| 11.05.2022 | - | WEST LAFAYETTE, Ind., May 11, 2022 /PRNewswire/ — On Target Laboratories, Inc., a privately held biotechnology company developing intraoperative molecular imaging agents to target and illuminate cancer during surgery, today announced that r... |
| 10.05.2022 | - | To accelerate clinical development of its best-in-class and first-in-class immuno-oncology programs |
| 16.03.2022 | Kither Biotech Raises €18.5 Million Series B and Appoints Dr. Vincent Metzler as Chief Executive Officer | Turin, Italy, 16 March 2022 Kither Biotech (Kither or the Company), a biopharmaceutical company developing novel therapies for rare respiratory diseases, today announces that it has raised €18.5 million in a Series B financing round and h... |
| 02.03.2022 | Epsilogen Announces Completion of Oversubscribed £30.75 Million ($41.20 Million) Series B Financing | Financing led by Novartis Venture Fund and joined by new investors 3B Future Health Fund, British Patient Capital, Schroders Capital and Caribou Property alongside founding investor Epidarex Capital and ALSA Ventures |
| 21.02.2022 | Labcorp Completes Acquisition of Personal Genome Diagnostics | BURLINGTON, N.C., Feb. 21, 2022 — Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has closed its acquisition of Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics with a portfolio of com... |
| 27.01.2022 | 3B Future Health promotes Marianne Bjørdal to Partner | 3B Future Health Ventures is pleased to announce the promotion of our colleague Marianne Bjørdal to Partner. Marianne joined 3B Future Health 3 years ago after a rewarding career as a researcher specialising in metabolism, neuroendocrine s... |
| 29.11.2021 | FDA Approves New Imaging Drug to Help Identify Ovarian Cancer Lesions | The U.S. Food and Drug Administration today approved Cytalux (pafolacianine), an imaging drug intended to assist surgeons in identifying ovarian cancer lesions. The drug is designed to improve the ability to locate additional ovarian cancer... |
| 23.11.2021 | Aadi Bioscience Announces FDA Approval of its First Product FYARRO™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa) | LOS ANGELES, Nov. 23, 2021 (GLOBE NEWSWIRE) — Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced... |
| 23.11.2021 | FDA approves sirolimus protein-bound particles for malignant perivascular epithelioid cell tumor | On November 22, 2021, the Food and Drug Administration approved sirolimus protein-bound particles for injectable suspension (albumin-bound) (Fyarro, Aadi Bioscience, Inc.) for adult patients with locally advanced unresectable or metastatic ... |
| 02.11.2021 | OncoResponse Announces Initiation of Phase 1 Trial of OR2805 – Human Monoclonal Antibody Derived from Elite Responder to Cancer Immunotherapy – in Patients with Advanced Cancer | SEATTLE, Nov. 2, 2021 /PRNewswire/ — OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of elite cancer responders, today announced initiation of a Phase 1/2 study of OR2805 in patients ... |
| 26.10.2021 | GenEp Raises $1.45 Million Seed Financing | Financing will support development of first-in-class CNS-selective sodium channel modulators |
| 06.10.2021 | OncoResponse Announces Presentations at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC 2021) | SEATTLE, Washington – October 6, 2021 – OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of elite cancer responders, today announced that it will present three abstracts at the upcomin... |
| 26.08.2021 | Aadi Bioscience Announces Closing of Merger with Aerpio Pharmaceuticals and $155M Private Placement | LOS ANGELES, Aug. 26, 2021 (GLOBE NEWSWIRE) — Aadi Bioscience, Inc. (“Aadiâ€) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway gen... |
| 10.08.2021 | Tesis Labs and Personal Genome Diagnostics Announce Collaboration to Advance Cancer Profiling and Treatment | BALTIMORE & HOUSTON–(BUSINESS WIRE)–Tesis Labs, a leader in targeted genetic sequencing, and Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced a new collaboration to maximize the power of genetic sequ... |
| 03.08.2021 | Personal Genome Diagnostics Appoints Jamie Platt, Ph.D., as Chief Operations Officer | BALTIMORE, Md.–(BUSINESS WIRE)– Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced the appointment of Jamie Platt, Ph.D., as Chief Operations Officer. Dr. Platt brings nearly 20 years of progressive leader... |
| 20.07.2021 | iOnctura Announces First Subject Dosed in Healthy Volunteer Study of Next Generation Autotaxin Inhibitor IOA-289 | • Safety, pharmacokinetic and pharmacodynamic readouts expected Q4 2021 |
| 07.07.2021 | ONCORESPONSE APPOINTS SEAN McCARTHY TO BOARD OF DIRECTORS | SEATTLE, Washington – July 7, 2021 – OncoResponse, a biotechnology company harnessing the
power of the human immune system to identify and develop novel monoclonal antibodies to
immunosuppressive myeloid targets for cancer immunotherapy... |
| 15.06.2021 | Personal Genome Diagnostics Enters Collaborative Partnership with Clinical Molecular Diagnostics
Laboratory of Major University Health System | BALTIMORE, MD, June 15, 2021 – Personal Genome Diagnostics Inc. (PGDx), a leader in cancer
genomics, today announced a collaborative partnership with the Duke University Health System (DUHS)
Clinical Molecular Diagnostics Laboratory. As p... |
| 15.06.2021 | UTILITY Therapeutics Preparing NDA Submission | LONDON, ENGLAND / ACCESSWIRE / June 15, 2021 /Â UTILITY therapeutics Ltd., a biotechnology company focused on the development and commercialization of two European-approved antibiotics for the treatment of urinary tract infections (UTIs) in... |
| 10.06.2021 | Gain Therapeutics Announces Issuance of Two New PCT Patents Covering GBA and GALC Modulator Compounds for Treatment of CNS Disorders | Activity of GBA and GALC Enzymes Play Key Roles in the Neurodegenerative Diseases and Lysosomal Storage Diseases |
| 19.05.2021 | Fore Biotherapeutics Strengthens Leadership Team with Executive and Board Appointments | Company appoints biotech industry experts Stacie Peacock Shepherd, M.D., Ph.D., as Chief Medical Officer and Nora Brennan as Chief Financial Officer |
| 17.05.2021 | Aerpio Pharmaceuticals and Aadi Bioscience Enter into a Definitive Merger Agreement | CINCINNATI and PACIFIC PALISADES, Calif., May 17, 2021 (GLOBE NEWSWIRE) — Aerpio Pharmaceuticals, Inc. (“Aerpioâ€) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2, and Aadi Bioscience, Inc.... |
| 11.05.2021 | OncoResponse Appoints Chris Russell as Chief Financial Officer | SEATTLE, May 11, 2021 (GLOBE NEWSWIRE) — OncoResponse, a biotechnology company harnessing the power of the human immune system to identify and develop novel monoclonal antibodies to immunosuppressive myeloid targets for cancer immunotherapy... |
| 11.05.2021 | UTILITY Therapeutics Announces Scientific Advisory Board | LONDON, UK / ACCESSWIRE / May 11, 2021 /Â UTILITY therapeutics Ltd., a biotechnology company focused on the U.S. development and commercialization of two European-approved antibiotics for the treatment of urinary tract infections (UTI), ann... |
| 10.05.2021 | Fore Biotherapeutics Opens U.S. Headquarters in Philadelphia’s Biotech Hub | Company to begin actively recruiting in Philadelphia, enabling creation of hundreds of new biotech jobs in the coming years |
| 13.04.2021 | Start-up GreenBone closes a EUR10m Series B round | GreenBone Ortho SpA, a specialist in the field of bone regeneration, has completed a EUR10 million Series B investment round led by existing shareholders – 3B Future Health Fund, Innogest SGR, Meta Group, CDP Venture Capital Sgr, Italian ... |
| 31.03.2021 | OncoResponse Raises $40.6 Million Series C Financing | – New capital will fund lead antibody, OR2805, through Phase 1 and 2 clinical studies |
| 24.03.2021 | - | Grand Duchy of Luxembourg – 3B FUTURE HEALTH GP S.a.r.l. is pleased to announce the launch of the 3B Future Health Fund II (“The Fundâ€), with Riccardo Braglia, Francesco Giavatto, Francesco Granata and Roberto De Ponti as General Partne... |
| 18.03.2021 | Gain Therapeutics Announces Pricing of Initial Public Offering of Common Stock | BETHESDA, Md., March 18, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (“Gainâ€) today announced the pricing of its initial public offering of 3,636,364 shares of its common stock at a price of $11.00 per share. The shares are expected... |
| 09.03.2021 | NeoPhore Announces £15.2m Financing to Advance DNA Mismatch Repair Pipeline | Round led by Claris Ventures with 2Invest, 3B Future Health Fund and Astellas Venture Management |
| 24.02.2021 | NovellusDx Establishes Fore Biotherapeutics U.S. as its Operating Company in the United States & Appoints Dieter Weinand as Chairman of the Board & Usama Malik as Chief Executive Officer and D... | Company launch and rebrand in the US reflects expert leadership in precision oncology and a new business model optimized for speed to market by hyper-targeting patient populations with unaddressed tumor mutations to match them with validate... |
| 04.02.2021 | - | BETHESDA, Md., Feb. 04, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc., (“Gainâ€) a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been targeted, ... |
| 21.09.2020 | Novellus Closes $57M Series C Financing | JERUSALEM–(BUSINESS WIRE)–Novellus, Ltd., a clinical-stage biotechnology company focused on precision oncology announced today that it has raised $57 million in a Series C financing round. The round was led by Pontifax, and joined by OrbiMe... |
| 10.09.2020 | - | BETHESDA, Md., Sept. 10, 2020 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc., (“Gainâ€) a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been targeted,... |
| 21.07.2020 | Gain Therapeutics, Inc. Announces Close of $10 Million Series B Financing | Eric I Richman appointed CEO and Director |
| 14.07.2020 | 3B Future Health Fund Announces New Investment in iOnctura | MONACO, PRINCIPALITY OF MONACO, 14 July 2020: 3B Future Health Fund, previously known as Helsinn Investment Fund S.A., SICAR, today announces that it has invested in iOnctura SA, a clinical stage biopharmaceutical company developing a pipel... |
| 08.06.2020 | QuantuMDx attains CE-IVD marking for SARS-CoV-2 Test | QuantuMDx Group today announces its SARS-CoV-2 detection assay has been CE-IVD marked under the In Vitro Diagnostics Directive (98/79/EC), enabling use within the European Union. |
| 14.04.2020 | OncoResponse Appoints Robert Lechleider, MD as Chief Medical Officer; Promotes Kamal Puri, PhD to Chief Scientific Officer | SEATTLE, WA / ACCESSWIRE / April 14, 2020 / OncoResponse, a biotechnology company
developing human antibodies as product candidates for multiple high-value targets associated
with immunosuppressive myeloid biology for application to cancer ... |
| 31.01.2020 | Lyfebulb and Helsinn Announce the Winners of the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award | MONACO, PRINCIPALITY OF MONACO, AND NEW YORK, NY, USA, January 31, 2020: Lyfebulb, a patient empowerment platform that connects patients with industry to support user-driven innovation toward solutions in chronic disease, and Helsinn, a Swi... |
| 30.01.2020 | The GreenBone bone substitute achieves CE certification | GreenBone received CE mark approval for the GreenBone Bone SubstituteTM |
| 15.07.2019 | Helsinn Investment Fund Announces First Exit | Luxembourg, 15 July 2019 Helsinn Investment Fund S.A, SICAR, a fund focused on early-stage investment opportunities in areas of high unmet patient need, today announces the fund first exit since launching in 2016. |
| 19.03.2019 | Winners of the Second Annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology Announced | MONACO, PRINCIPALITY OF MONACO and NEW YORK, NY, MARCH 19, 2019: |
| 19.02.2019 | Helsinn Investment Fund Invests €1 Million in Gain Therapeutics | Luxembourg, 19 February 2019: Helsinn Investment Fund S.A, SICAR, a fund focused on early-stage investment opportunities in areas of high unmet patient need, today announces that it has made a €1 Million investment in Gain Therapeutics SA... |
| 23.01.2019 | QuantuMDx & St George’s begin field study: cervical cancer screening test | To coincide with Cervical Cancer Prevention Week, QuantuMDx Group has announced the start of a field study with St George’s, University of London, to evaluate its human papilloma virus (HPV) assay which will provide a solution for cervic... |
| 30.04.2018 | NovellusDx Announces It Has Completed an Equity Financing of $6 Million | Jerusalem, Israel, 30 April 2018 – NovellusDx, the leader in functional genomics, today announced it has completed an equity financing of $6 million. The financing round is with the participation of Helsinn Investment Fund S.A. SICAR, par... |
| 28.03.2018 | Winners of the Inaugural Lyfebulb-Helsinn Innovation Summit & Awards in Oncology Announced | Lorenzo Pradella of GreenBone Ortho, srl has been selected from eleven finalists as the winner of the first-ever Lyfebulb-Helsinn Innovation Award in Oncology. |
| 14.03.2018 | On Target Laboratories Raises Additional Capital from H.I.G. BioHealth Partners, Elevate Ventures and Helsinn | WEST LAFAYETTE, Ind. 14 March 2018 – On Target Laboratories, Inc., a privately-held biotechnology company that is developing tumour-targeted fluorescent dyes to improve cancer surgery, has secured additional financing as part of its Serie... |
| 30.01.2018 | Helsinn and the Scientific Centre of Monaco Sign Collaboration Agreement | Lugano, Switzerland, 30 January 2018 – Helsinn International Services, Sarl, a Monaco-based affiliate of the Swiss Pharmaceutical Group focused on building quality cancer care products, and the Scientific Centre of Monaco (CSM), today ann... |
| 05.09.2017 | AMAL Therapeutics Raises €8 Million (CHF 8.8 Million) in First Closing of Series B Financing Round | Financing round co-led by Boehringer Ingelheim Venture Fund, BioMedPartners and Helsinn Investment Fund |
| 16.06.2017 | Helsinn Investment Fund Leads the Financial Round in GreenBone | Lugano, Switzerland, 16 June 2017: Helsinn Investment Fund S.A., a fund focused on early-stage investments in areas of high unmet patient need, today announces that it has made a Euro 2M investment in GreenBone, a privately-held developer o... |
| 08.05.2017 | Helsinn Investment Fund Invests in Aadi Bioscience | Luxembourg, 8 May 2017: Helsinn Investment Fund S.A, a fund focused on early-stage investment opportunities in areas of high unmet patient need, today announces that it has made a $2 million investment in Aadi Bioscience, Inc., U.S., a clin... |
| 10.10.2016 | Helsinn Investment Fund Invests £2.0 Million in QuantuMDx | Lugano, Switzerland, 10 October 2016: Helsinn Investment Fund S.A., a fund focused on early-stage investments in areas of high unmet patient need, today announces that it has made a £2.0 million investment in QuantuMDx Group, a privately-h... |
| 10.10.2016 | Helsinn Investment Fund to Invest $3.5 Million in OncoResponse | Lugano, Switzerland, 10 October 2016: Helsinn Investment Fund S.A, a fund focused on early-stage investments in areas of high unmet patient need, today announces that on 23 September 2016, it made a $3.5 million investment in OncoResponse, ... |
| 10.10.2016 | Helsinn Group Introduces Helsinn Investment Fund | Lugano, Switzerland, 10 October 2016: Helsinn, the Swiss Pharmaceutical Group focused on building quality cancer care, today introduces Helsinn Investment Fund S.A. (“the Fundâ€), a fund focused on early-stage investment opportunities in... |
| 08.08.2016 | Helsinn Group and MEI Pharma Enter Strategic Agreement for the Development and Commercialisation of Pracinostat for the Treatment of Acute Myeloid Leukaemia and Other Haematologic Diseases | MEI Pharma to receive $20 million in near-term cash payments, plus up to $444 million in potential milestone payments as well as royalties on future sales. |
